Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
What You Missed On Wall Street On Friday » 13:14
11/25/22
11/25
13:14
11/25/22
13:14
ATVI

Activision Blizzard

$73.56 /

-3.005 (-3.92%)

, MSFT

Microsoft

$247.53 /

-0.13 (-0.05%)

, AAPL

Apple

$148.06 /

-3.025 (-2.00%)

, MANU

Manchester United

$21.10 /

+2.3 (+12.23%)

, CRM

Salesforce

$153.44 /

+1.335 (+0.88%)

, YNDX

Yandex

$18.93 /

+ (+0.00%)

, TSLA

Tesla

$182.73 /

-0.53 (-0.29%)

, GOOGL

Alphabet

$97.51 /

-0.965 (-0.98%)

, GOOG

Alphabet

$97.65 /

-1.22 (-1.23%)

, GNRC

Generac

$105.41 /

-1.61 (-1.50%)

, KFRC

Kforce

$58.95 /

-0.96 (-1.60%)

, KFY

Korn Ferry

$56.20 /

-0.34 (-0.60%)

, COUP

Coupa Software

$62.71 /

+3.9 (+6.63%)

, LYG

Lloyds Banking

$2.23 /

+0.085 (+3.97%)

, LU

Lufax

$1.40 /

-0.36 (-20.51%)

, DB

Deutsche Bank

$10.80 /

+0.155 (+1.46%)

, JPM

JPMorgan

$136.65 /

+0.175 (+0.13%)

, IRDM

Iridium

$52.46 /

+0.7 (+1.35%)

, CANF

Can-Fite BioPharma

/

+

, BILI

Bilibili

$12.32 /

-0.965 (-7.26%)

, SPPI

Spectrum

/

+

, GOEV

Canoo

$1.14 /

+0.06 (+5.58%)

, MMAT

Meta Materials

$1.93 /

+0.085 (+4.62%)

, AMD

AMD

$75.19 /

-1.19 (-1.56%)

, NVDA

Nvidia

$162.83 /

-2.42 (-1.46%)

, WDAY

Workday

$149.21 /

-0.03 (-0.02%)

Get caught up quickly on…

ShowHide Related Items >><<
YNDX Yandex
$18.93 /

+ (+0.00%)

WDAY Workday
$149.21 /

-0.03 (-0.02%)

TSLA Tesla
$182.73 /

-0.53 (-0.29%)

SPPI Spectrum
/

+

NVDA Nvidia
$162.83 /

-2.42 (-1.46%)

MSFT Microsoft
$247.53 /

-0.13 (-0.05%)

MMAT Meta Materials
$1.93 /

+0.085 (+4.62%)

MANU Manchester United
$21.10 /

+2.3 (+12.23%)

LYG Lloyds Banking
$2.23 /

+0.085 (+3.97%)

LU Lufax
$1.40 /

-0.36 (-20.51%)

KFY Korn Ferry
$56.20 /

-0.34 (-0.60%)

KFRC Kforce
$58.95 /

-0.96 (-1.60%)

JPM JPMorgan
$136.65 /

+0.175 (+0.13%)

IRDM Iridium
$52.46 /

+0.7 (+1.35%)

GOOGL Alphabet
$97.51 /

-0.965 (-0.98%)

GOOG Alphabet
$97.65 /

-1.22 (-1.23%)

GOEV Canoo
$1.14 /

+0.06 (+5.58%)

GNRC Generac
$105.41 /

-1.61 (-1.50%)

DB Deutsche Bank
$10.80 /

+0.155 (+1.46%)

CRM Salesforce
$153.44 /

+1.335 (+0.88%)

COUP Coupa Software
$62.71 /

+3.9 (+6.63%)

CANF Can-Fite BioPharma
/

+

BILI Bilibili
$12.32 /

-0.965 (-7.26%)

ATVI Activision Blizzard
$73.56 /

-3.005 (-3.92%)

AMD AMD
$75.19 /

-1.19 (-1.56%)

AAPL Apple
$148.06 /

-3.025 (-2.00%)

ATVI Activision Blizzard
$73.56 /

-3.005 (-3.92%)

11/22/22 Baird
Activision Blizzard upgraded to Outperform from Neutral at Baird
11/16/22 Deutsche Bank
Activision Blizzard price target lowered to $83 from $84 at Deutsche Bank
11/15/22 MKM Partners
MKM upgrades Activision Blizzard to Buy, sees stock discount growth potential
11/15/22 MKM Partners
Activision Blizzard upgraded to Buy from Neutral at MKM Partners
MSFT Microsoft
$247.53 /

-0.13 (-0.05%)

11/10/22 Raymond James
Activision Blizzard upgraded to Outperform from Market Perform at Raymond James
AAPL Apple
$148.06 /

-3.025 (-2.00%)

11/23/22 Wedbush
iPhone demand into Black Friday may put Apple in 'major shortage,' says Wedbush
11/22/22 Canaccord
Apple iPhone demand remains strong, supply could be issue, says Canaccord
11/21/22 JPMorgan
Apple likely past trough for iPhone Pro supply, says JPMorgan
11/21/22 Craig-Hallum
Craig-Hallum bullish on Globalstar amid upcoming Apple support for Band 53
MANU Manchester United
$21.10 /

+2.3 (+12.23%)

11/23/22 Jefferies
Jefferies expects 'competitive process' for Manchester United
06/02/22 Deutsche Bank
Manchester United undervalued after selloff, says Deutsche Bank
03/21/22 Deutsche Bank
Manchester United upgraded on 'value disconnect' at Deutsche Bank
03/21/22 Deutsche Bank
Manchester United upgraded to Buy from Hold at Deutsche Bank
CRM Salesforce
$153.44 /

+1.335 (+0.88%)

11/22/22 Deutsche Bank
Salesforce price target lowered to $220 from $255 at Deutsche Bank
11/22/22 Morgan Stanley
Salesforce lowered bar 'looks achievable,' says Morgan Stanley
11/22/22 Wells Fargo
Salesforce price target lowered to $190 from $220 at Wells Fargo
11/20/22 Jefferies
Salesforce price target lowered to $240 from $250 at Jefferies
YNDX Yandex
$18.93 /

+ (+0.00%)

02/17/22 Citi
Yandex price target lowered to $70 from $75 at Citi
01/18/22 Citi
Yandex price target lowered to $75 from $90 at Citi
12/16/21 HSBC
Yandex upgraded to Buy from Hold at HSBC
TSLA Tesla
$182.73 /

-0.53 (-0.29%)

11/23/22 Morgan Stanley
Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff
11/23/22 Citi
Tesla upgraded to Neutral from Sell at Citi
11/10/22 Wedbush
Tesla removed from 'Best Ideas' list at Wedbush
11/02/22 Bernstein
Bernstein analysis shows Tesla total software run rate revenues of $290M/quarter
GOOGL Alphabet
$97.51 /

-0.965 (-0.98%)

11/23/22 JMP Securities
Alphabet price target lowered to $132 from $145 at JMP Securities
11/15/22 Morgan Stanley
Alphabet price target lowered to $120 from $125 at Morgan Stanley
11/10/22 BofA
BofA downgrades Viant, sees things getting worse before better
11/09/22 Oppenheimer
Trade Desk price target lowered to $60 from $78 at Oppenheimer
GOOG Alphabet
$97.65 /

-1.22 (-1.23%)

10/31/22 Morgan Stanley
ADT Inc. resumed with an Equal Weight at Morgan Stanley
GNRC Generac
$105.41 /

-1.61 (-1.50%)

11/25/22 Argus
Generac cut to Hold at Argus on supply chain issues
11/25/22 Argus
Generac downgraded to Hold from Buy at Argus
11/04/22 Wells Fargo
Generac price target lowered to $155 from $175 at Wells Fargo
11/03/22 Cowen
Generac price target lowered to $157 from $179 at Cowen
KFRC Kforce
$58.95 /

-0.96 (-1.60%)

11/25/22 William Blair
William Blair downgrades Kforce, Korn Ferry on staffing sector deceleration
11/25/22 William Blair
Kforce downgraded to Market Perform from Outperform at William Blair
08/05/22 Baird
Kforce price target lowered to $70 from $80 at Baird
07/15/22 Truist
Kforce price target lowered to $65 from $80 at Truist
KFY Korn Ferry
$56.20 /

-0.34 (-0.60%)

11/25/22 William Blair
Korn Ferry downgraded to Market Perform from Outperform at William Blair
09/08/22 Baird
Korn/Ferry price target lowered to $64 from $72 at Baird
06/23/22 Baird
Korn/Ferry price target lowered to $72 from $90 at Baird
COUP Coupa Software
$62.71 /

+3.9 (+6.63%)

11/25/22 Raymond James
Coupa Software takeout would be 'reasonable' at $68-$80, say Raymond James
11/25/22 Truist
Truist sees 'scarcity value' in Coupa platform, keeps $75 target
11/25/22 BofA
Coupa has strategic value, could also represent attractive PE target, says BofA
11/23/22 Needham
Coupa takeout price would need to be closer to $90, says Needham
LYG Lloyds Banking
$2.23 /

+0.085 (+3.97%)

11/25/22 RBC Capital
Lloyds Banking upgraded to Outperform from Underperform at RBC Capital
10/28/22 JPMorgan
Lloyds Banking price target raised to 58 GBp from 56 GBp at JPMorgan
10/28/22 RBC Capital
Lloyds Banking price target raised to 44 GBp from 42 GBp at RBC Capital
10/20/22 Barclays
Lloyds Banking price target lowered to 50 GBp from 55 GBp at Barclays
LU Lufax
$1.40 /

-0.36 (-20.51%)

11/25/22 HSBC
Lufax downgraded to Hold from Buy at HSBC
11/25/22 Citi
Lufax price target lowered to $3.52 from $6.06 at Citi
11/25/22 Daiwa
Lufax downgraded to Hold from Buy at Daiwa
11/25/22 JPMorgan
Lufax downgraded to Underweight from Overweight at JPMorgan
DB Deutsche Bank
$10.80 /

+0.155 (+1.46%)

11/25/22 RBC Capital
Deutsche Bank upgraded to Outperform from Sector Perform at RBC Capital
11/11/22 Barclays
Deutsche Bank price target raised to EUR 11.50 from EUR 11 at Barclays
10/31/22 RBC Capital
Deutsche Bank price target raised to EUR 11.50 from EUR 11 at RBC Capital
10/27/22 Credit Suisse
Deutsche Bank price target raised to EUR 10.50 from EUR 10 at Credit Suisse
JPM JPMorgan
$136.65 /

+0.175 (+0.13%)

10/17/22 Citi
JPMorgan shares offer 'excellent entry point,' says Citi
10/17/22 BMO Capital
JPMorgan price target raised to $158 from $149 at BMO Capital
10/05/22 Morgan Stanley
JPMorgan price target lowered to $126 from $127 at Morgan Stanley
10/04/22 Citi
Citi opens 'positive catalyst watch' on JPMorgan into results
IRDM Iridium
$52.46 /

+0.7 (+1.35%)

11/25/22 William Blair
Report about Galaxy S23 'significant positive' for Iridium, says William Blair
10/21/22 Raymond James
Iridium price target raised to $60 from $51 at Raymond James
10/19/22 Barclays
Iridium downgraded to Equal Weight from Overweight at Barclays
10/17/22 Morgan Stanley
Iridium price target raised to $64 from $50 at Morgan Stanley
CANF Can-Fite BioPharma
/

+

11/30/21 Alliance Global Partners
Can-Fite price target lowered to $8.25 from $9 at Alliance Global Partners
BILI Bilibili
$12.32 /

-0.965 (-7.26%)

11/25/22 BofA
Bilibili price target raised to $13.50 from $11.50 at BofA
11/02/22 BofA
Bilibili downgraded to Neutral at BofA on 'challenging' monetization outlook
11/02/22 BofA
Bilibili downgraded to Neutral from Buy at BofA
10/28/22 Barclays
Bilibili price target lowered to $13 from $21 at Barclays
SPPI Spectrum
/

+

11/25/22 H.C. Wainwright
Spectrum price target lowered to $4 from $6 at H.C. Wainwright
11/16/22 B. Riley
Spectrum downgraded to Neutral from Buy at B. Riley
09/23/22 H.C. Wainwright
Spectrum price target lowered to $6 from $9 at H.C. Wainwright
09/23/22 B. Riley
Spectrum price target lowered to $1.50 from $4 at B. Riley
GOEV Canoo
$1.14 /

+0.06 (+5.58%)

11/10/22 R.F. Lafferty
Canoo price target lowered to $6 from $15 at R.F. Lafferty
09/15/22 Stifel
Canoo initiated with a Buy at Stifel
08/09/22 Roth Capital
Canoo downgraded to Neutral at Roth Capital on increased need for cash
08/09/22 Roth Capital
Canoo downgraded to Neutral from Buy at Roth Capital
MMAT Meta Materials
$1.93 /

+0.085 (+4.62%)

AMD AMD
$75.19 /

-1.19 (-1.56%)

11/15/22 Credit Suisse
Intel assumed with a Neutral at Credit Suisse
11/15/22 Credit Suisse
AMD assumed with an Outperform at Credit Suisse
11/14/22 UBS
UBS upgraded AMD to Buy, expects PC 'replenishment' during FY23
11/14/22 Baird
AMD upgraded to Outperform at Baird on strong reception of Genoa
NVDA Nvidia
$162.83 /

-2.42 (-1.46%)

11/17/22 Needham
Nvidia price target raised to $200 from $155 at Needham
11/17/22 Jefferies
Nvidia fundamentals bottoming, should grow through 2023, says Jefferies
11/17/22 Stifel
Nvidia price target raised to $175 from $165 at Stifel
11/17/22 Wedbush
Nvidia price target raised to $175 from $160 at Wedbush
WDAY Workday
$149.21 /

-0.03 (-0.02%)

11/22/22 DA Davidson
Workday price target lowered to $205 from $220 at DA Davidson
11/21/22 BMO Capital
Workday price target lowered to $195 from $217 at BMO Capital
11/21/22 Loop Capital
Workday downgraded to Hold from Buy at Loop Capital
11/18/22 Barclays
Workday price target lowered to $198 from $208 at Barclays
YNDX Yandex
$18.93 /

+ (+0.00%)

WDAY Workday
$149.21 /

-0.03 (-0.02%)

TSLA Tesla
$182.73 /

-0.53 (-0.29%)

SPPI Spectrum
/

+

NVDA Nvidia
$162.83 /

-2.42 (-1.46%)

MSFT Microsoft
$247.53 /

-0.13 (-0.05%)

MANU Manchester United
$21.10 /

+2.3 (+12.23%)

LYG Lloyds Banking
$2.23 /

+0.085 (+3.97%)

LU Lufax
$1.40 /

-0.36 (-20.51%)

KFY Korn Ferry
$56.20 /

-0.34 (-0.60%)

KFRC Kforce
$58.95 /

-0.96 (-1.60%)

JPM JPMorgan
$136.65 /

+0.175 (+0.13%)

IRDM Iridium
$52.46 /

+0.7 (+1.35%)

GOOGL Alphabet
$97.51 /

-0.965 (-0.98%)

GOEV Canoo
$1.14 /

+0.06 (+5.58%)

GNRC Generac
$105.41 /

-1.61 (-1.50%)

DB Deutsche Bank
$10.80 /

+0.155 (+1.46%)

CRM Salesforce
$153.44 /

+1.335 (+0.88%)

COUP Coupa Software
$62.71 /

+3.9 (+6.63%)

CANF Can-Fite BioPharma
/

+

BILI Bilibili
$12.32 /

-0.965 (-7.26%)

ATVI Activision Blizzard
$73.56 /

-3.005 (-3.92%)

AMD AMD
$75.19 /

-1.19 (-1.56%)

AAPL Apple
$148.06 /

-3.025 (-2.00%)

YNDX Yandex
$18.93 /

+ (+0.00%)

TSLA Tesla
$182.73 /

-0.53 (-0.29%)

NVDA Nvidia
$162.83 /

-2.42 (-1.46%)

MSFT Microsoft
$247.53 /

-0.13 (-0.05%)

MANU Manchester United
$21.10 /

+2.3 (+12.23%)

LYG Lloyds Banking
$2.23 /

+0.085 (+3.97%)

LU Lufax
$1.40 /

-0.36 (-20.51%)

JPM JPMorgan
$136.65 /

+0.175 (+0.13%)

GOOGL Alphabet
$97.51 /

-0.965 (-0.98%)

GOEV Canoo
$1.14 /

+0.06 (+5.58%)

GNRC Generac
$105.41 /

-1.61 (-1.50%)

DB Deutsche Bank
$10.80 /

+0.155 (+1.46%)

CRM Salesforce
$153.44 /

+1.335 (+0.88%)

COUP Coupa Software
$62.71 /

+3.9 (+6.63%)

BILI Bilibili
$12.32 /

-0.965 (-7.26%)

ATVI Activision Blizzard
$73.56 /

-3.005 (-3.92%)

AMD AMD
$75.19 /

-1.19 (-1.56%)

AAPL Apple
$148.06 /

-3.025 (-2.00%)

YNDX Yandex
$18.93 /

+ (+0.00%)

WDAY Workday
$149.21 /

-0.03 (-0.02%)

TSLA Tesla
$182.73 /

-0.53 (-0.29%)

SPPI Spectrum
/

+

MANU Manchester United
$21.10 /

+2.3 (+12.23%)

LYG Lloyds Banking
$2.23 /

+0.085 (+3.97%)

LU Lufax
$1.40 /

-0.36 (-20.51%)

KFY Korn Ferry
$56.20 /

-0.34 (-0.60%)

JPM JPMorgan
$136.65 /

+0.175 (+0.13%)

GOOGL Alphabet
$97.51 /

-0.965 (-0.98%)

GOEV Canoo
$1.14 /

+0.06 (+5.58%)

GNRC Generac
$105.41 /

-1.61 (-1.50%)

DB Deutsche Bank
$10.80 /

+0.155 (+1.46%)

CRM Salesforce
$153.44 /

+1.335 (+0.88%)

CANF Can-Fite BioPharma
/

+

BILI Bilibili
$12.32 /

-0.965 (-7.26%)

ATVI Activision Blizzard
$73.56 /

-3.005 (-3.92%)

AMD AMD
$75.19 /

-1.19 (-1.56%)

AAPL Apple
$148.06 /

-3.025 (-2.00%)

WDAY Workday
$149.21 /

-0.03 (-0.02%)

TSLA Tesla
$182.73 /

-0.53 (-0.29%)

SPPI Spectrum
/

+

NVDA Nvidia
$162.83 /

-2.42 (-1.46%)

MSFT Microsoft
$247.53 /

-0.13 (-0.05%)

MMAT Meta Materials
$1.93 /

+0.085 (+4.62%)

MANU Manchester United
$21.10 /

+2.3 (+12.23%)

LU Lufax
$1.40 /

-0.36 (-20.51%)

JPM JPMorgan
$136.65 /

+0.175 (+0.13%)

GOOGL Alphabet
$97.51 /

-0.965 (-0.98%)

GOOG Alphabet
$97.65 /

-1.22 (-1.23%)

GOEV Canoo
$1.14 /

+0.06 (+5.58%)

GNRC Generac
$105.41 /

-1.61 (-1.50%)

DB Deutsche Bank
$10.80 /

+0.155 (+1.46%)

CRM Salesforce
$153.44 /

+1.335 (+0.88%)

COUP Coupa Software
$62.71 /

+3.9 (+6.63%)

BILI Bilibili
$12.32 /

-0.965 (-7.26%)

ATVI Activision Blizzard
$73.56 /

-3.005 (-3.92%)

AMD AMD
$75.19 /

-1.19 (-1.56%)

AAPL Apple
$148.06 /

-3.025 (-2.00%)

Recommendations
Spectrum price target lowered to $4 from $6 at H.C. Wainwright » 11:58
11/25/22
11/25
11:58
11/25/22
11:58
SPPI

Spectrum

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White lowered the firm's price target on Spectrum Pharmaceuticals to $4 from $6 and keeps a Buy rating on the shares after the company received a complete response letter from the FDA regarding poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer harboring HER2 exon 20 insertion mutations. The analyst is not surprised by the CRL following the negative recommendation from the FDA panel. He removed poziotinib from his valuation but believes there is a possibility for Spectrum to sell or partner poziotinib. This is a "potential opportunity as an upside call option," writes White.

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

11/16/22 B. Riley
Spectrum downgraded to Neutral from Buy at B. Riley
09/23/22 H.C. Wainwright
Spectrum price target lowered to $6 from $9 at H.C. Wainwright
09/23/22 B. Riley
Spectrum price target lowered to $1.50 from $4 at B. Riley
09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
SPPI Spectrum
/

+

SPPI Spectrum
/

+

SPPI Spectrum
/

+

Hot Stocks
Spectrum receives CRL from FDA regarding NDA for poziotinib » 06:02
11/25/22
11/25
06:02
11/25/22
06:02
SPPI

Spectrum

/

+

Spectrum Pharmaceuticals…

Spectrum Pharmaceuticals announced that the company has received a Complete Response Letter from the U.S. FDA regarding Spectrum's New Drug Application for poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer harboring HER2 exon 20 insertion mutations. The FDA issued a CRL indicating the poziotinib application cannot be approved in its present form. Based on the CRL, the Company would have to generate additional data including a randomized controlled study prior to approval. "While we are not surprised by the CRL given the ODAC recommendation in September, we are disappointed. After multiple interactions with the FDA since ODAC, and following careful consideration, we have made the strategic decision to immediately de-prioritize the poziotinib program," said Tom Riga, President and CEO of Spectrum Pharmaceuticals. "We continue to believe that poziotinib could present a meaningful treatment option for patients with this rare form of lung cancer, for whom other therapies have failed." The company will de-prioritize poziotinib program activities, effective immediately, and is in the process of reducing its R&D workforce by approximately 75%. Based on the anticipated cost savings from the restructuring, Spectrum believes it will be able to generate the working capital required to support its strategic refocusing through 2024.

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

11/16/22 B. Riley
Spectrum downgraded to Neutral from Buy at B. Riley
09/23/22 H.C. Wainwright
Spectrum price target lowered to $6 from $9 at H.C. Wainwright
09/23/22 B. Riley
Spectrum price target lowered to $1.50 from $4 at B. Riley
09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
SPPI Spectrum
/

+

SPPI Spectrum
/

+

SPPI Spectrum
/

+

Over a week ago
Downgrade
Spectrum downgraded to Neutral from Buy at B. Riley » 07:54
11/16/22
11/16
07:54
11/16/22
07:54
SPPI

Spectrum

/

+

B. Riley analyst Mayank…

B. Riley analyst Mayank Mamtani downgraded Spectrum Pharmaceuticals to Neutral from Buy with a price target of $1, down from $1.50. The analyst sees "elevated uncertainty" on the prospects for poziotinib to receive an FDA approval at upcoming November 24 action date after an FDA panel voted 4-9 against the recommendation of granting accelerated approval. In addition, Spectrum has a challenging near-term pipeline catalyst profile given the low likelihood to continued poziotinib development in the ZENITH20 program and deprioritization of the early-stage pipeline announced in Q1 of 2021, says the analyst.

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

09/23/22 H.C. Wainwright
Spectrum price target lowered to $6 from $9 at H.C. Wainwright
09/23/22 B. Riley
Spectrum price target lowered to $1.50 from $4 at B. Riley
09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
03/21/22 B. Riley
Spectrum price target lowered to $4 from $6 at B. Riley
SPPI Spectrum
/

+

SPPI Spectrum
/

+

SPPI Spectrum
/

+

Earnings
Spectrum reports Q3 EPS (12c), consensus (15c) » 16:10
11/10/22
11/10
16:10
11/10/22
16:10
SPPI

Spectrum

/

+

Reports company had a…

Reports company had a total cash, cash equivalents, and marketable securities balance of approximately $100.3M at September 30. "The approval of ROLVEDON marks a significant accomplishment for Spectrum and our partner Hanmi Pharmaceutical. We are proud that the product became commercially available in October and are excited to be competing in an estimated $2 billion market opportunity. Importantly, we have been preparing for this milestone and have the financial runway to support ROLVEDON in the marketplace. While we are disappointed by the ODAC vote on poziotinib, we are awaiting the final response from the FDA and will continue to act in the best interest of the Company, our shareholders, and the patients who need our medicines," said Tom Riga, President and CEO of Spectrum Pharmaceuticals.

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

09/23/22 H.C. Wainwright
Spectrum price target lowered to $6 from $9 at H.C. Wainwright
09/23/22 B. Riley
Spectrum price target lowered to $1.50 from $4 at B. Riley
09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
03/21/22 B. Riley
Spectrum price target lowered to $4 from $6 at B. Riley
SPPI Spectrum
/

+

SPPI Spectrum
/

+

Over a month ago
Hot Stocks
Spectrum announces commercial availability of Rolvedon » 07:12
10/21/22
10/21
07:12
10/21/22
07:12
SPPI

Spectrum

/

+

Spectrum announced the…

Spectrum announced the commercial availability of Rolvedon injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Rolvedon received FDA approval in September.

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

09/23/22 H.C. Wainwright
Spectrum price target lowered to $6 from $9 at H.C. Wainwright
09/23/22 B. Riley
Spectrum price target lowered to $1.50 from $4 at B. Riley
09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
03/21/22 B. Riley
Spectrum price target lowered to $4 from $6 at B. Riley
SPPI Spectrum
/

+

SPPI Spectrum
/

+

Recommendations
Spectrum price target lowered to $6 from $9 at H.C. Wainwright » 11:07
09/23/22
09/23
11:07
09/23/22
11:07
SPPI

Spectrum

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White lowered the firm's price target on Spectrum to $6 from $9 and keeps a Buy rating on the shares after lowering his view on the odds of of accelerated approval for poziotinib to 15% from 50% following a panel of FDA advisors having voted 9-4 that the current benefits of poziotinib did not outweigh its risks in patients with previously treated, locally advanced or metastatic non-small cell lung cancer harboring HER2 exon 20 insertion mutations. While noting that the FDA does not have to follow the recommendations of the ODAC, White believes the ODAC vote is negative for potential approval of poziotinib, adding that if accelerated approval is not achieved, then poziotinib could be ultimately approved with the confirmatory trial if Spectrum decides to proceed with it. His revised target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rolvedon and poziotinib.

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

09/23/22 B. Riley
Spectrum price target lowered to $1.50 from $4 at B. Riley
09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
03/21/22 B. Riley
Spectrum price target lowered to $4 from $6 at B. Riley
SPPI Spectrum
/

+

SPPI Spectrum
/

+

Recommendations
Spectrum price target lowered to $1.50 from $4 at B. Riley » 07:29
09/23/22
09/23
07:29
09/23/22
07:29
SPPI

Spectrum

/

+

B. Riley analyst Mayank…

B. Riley analyst Mayank Mamtani lowered the firm's price target on Spectrum to $1.50 from $4 and keeps a Buy rating on the shares after an FDA panel voted 4-9 against the recommendation of granting accelerated approval to the company's lead program, poziotinib in previously treated, HER2 exon 20 insertion mutant non-small cell lung cancer patients. The vote is disappointing, but not unexpected, Mamtani tells investors in a research note. He sees an "uphill battle" ahead for poziotinib "with an NDA submission that may have been premature." Mamtani lowered his probability of technical and regulatory success from 50% to 20% and pushed out timelines for recognition of any meaningful poziotinib-related product sales.

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
03/21/22 B. Riley
Spectrum price target lowered to $4 from $6 at B. Riley
SPPI Spectrum
/

+

SPPI Spectrum
/

+

Hot Stocks
Spectrum: FDA panel votes 9-4 that benefits of poziotinib did not outweigh risks » 15:32
09/22/22
09/22
15:32
09/22/22
15:32
SPPI

Spectrum

/

+

Spectrum Pharmaceuticals…

Spectrum Pharmaceuticals announced that the U.S. FDA Oncologic Drugs Advisory Committee met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer harboring HER2 exon 20 insertion mutations. The committee voted 9-4 that the current benefits of poziotinib did not outweigh its risks. "We are disappointed by the outcome of the ODAC meeting, as patients with NSCLC HER2 exon 20 insertion mutations are in need of additional effective and safe therapies," stated Tom Riga, President and CEO of Spectrum Pharmaceuticals. "We plan to carefully evaluate our options for this program as we approach the November 24, 2022, PDUFA date. We would like to thank lung cancer patients and their families, as well as investigators and their staff, for their support."

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
03/21/22 B. Riley
Spectrum price target lowered to $4 from $6 at B. Riley
SPPI Spectrum
/

+

SPPI Spectrum
/

+

Conference/Events
FDA Oncologic Drugs Advisory Committee to hold a virtual meeting » 08:45
09/22/22
09/22
08:45
09/22/22
08:45
SPPI

Spectrum

/

+

The Committee discusses…

The Committee discusses Spectrum Pharmaceuticals' New Drug Application (NDA) 215643 for Poziotinib tablets for the proposed indication for treatment of patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 20 insertion mutations. The Committee will also hear an update on Oncopeptides A.B.'s New Drug Application (NDA) 214383 for PEPAXTO (melphalan flufenamide) for injection in the virtual meeting being held on September 22 at 9 am. Webcast Link

ShowHide Related Items >><<
SPPI Spectrum
/

+

SPPI Spectrum
/

+

09/20/22 H.C. Wainwright
Spectrum price target lowered to $9 from $12 at H.C. Wainwright
03/21/22 B. Riley
Spectrum price target lowered to $4 from $6 at B. Riley
SPPI Spectrum
/

+

SPPI Spectrum
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.